Autolus Therapeutics plc (AUTL)

Market Cap	396.55M -3.9%
Revenue (ttm)	75.39M +644.9%
Net Income	-287.53M
EPS	-1.08
Shares Out	266.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,267,122
Open	1.490
Previous Close	1.480
Day's Range	1.450 - 1.500
52-Week Range	1.150 - 2.700
Beta	2.03
Analysts	Strong Buy
Price Target	8.50 (+470.47%)
Earnings Date	May 7, 2026

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 22, 2018
• Employees: 754
• Stock Exchange: NASDAQ
• Ticker Symbol: AUTL
• Website: https://www.autolus.com

Financial Performance

In 2025, Autolus Therapeutics's revenue was $75.39 million, an increase of 644.94% compared to the previous year's $10.12 million. Losses were -$287.53 million, 30.3% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for AUTL stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 470.47% from the latest price.

Price Target

$8.5

(470.47% upside)

Analyst Consensus: Strong Buy